Cliical Trials: Multiplicity & Subgroup Analyses

Multiplicity Considerations in Real-World Evidence and External Controls Introduction to Multiplicity in Clinical Trials Clinical trials are crucial for developing safe and effective therapies, particularly for conditions like ankylosing spondylitis. However, the evaluation of clinical data can become complex due to multiplicity issues. Multiplicity refers to the problem that arises when multiple comparisons or endpoints…

Read More “Multiplicity Considerations in Real-World Evidence and External Controls” »

Handling Biomarker-Defined Subgroups and Companion Diagnostics in Clinical Trials In the ever-evolving landscape of clinical trials, understanding how to effectively manage biomarker-defined subgroups and companion diagnostics is crucial. This step-by-step tutorial provides essential guidance for clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU. The focus will be on the…

Read More “Handling Biomarker-Defined Subgroups and Companion Diagnostics” »

Subgroup Analyses in Rare Disease and Small Population Trials Subgroup Analyses in Rare Disease and Small Population Trials Subgroup analyses are critical components of clinical trials that allow researchers to explore treatment effects among predefined patient subsets. Particularly in rare disease and small population trials, where sample sizes limit statistical power, the insights derived from…

Read More “Subgroup Analyses in Rare Disease and Small Population Trials” »

Integrating Multiplicity Controls With Interim Analyses and Estimands Integrating Multiplicity Controls With Interim Analyses and Estimands In the realm of clinical trials, particularly in regulatory environments such as those governed by the FDA, EMA, and MHRA, the design and analysis of studies have become increasingly sophisticated. Specifically, the intertwining of multiplicity controls with interim analyses…

Read More “Integrating Multiplicity Controls With Interim Analyses and Estimands” »

Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions The complexity of clinical trials often leads to challenges associated with multiplicity, which can significantly impact the reliability of trial conclusions. In this tutorial, we provide detailed case studies that exemplify these pitfalls, particularly centered around the lecanemab clinical…

Read More “Case Studies: Multiplicity Pitfalls That Undermined Trial Conclusions” »

Documentation of Multiplicity Strategy in Submission Packages Documentation of Multiplicity Strategy in Submission Packages In the realm of clinical trials, the documentation of multiplicity strategies within submission packages is a critical component of ensuring regulatory compliance and scientific validity. Given the multifaceted nature of clinical research, particularly in the context of subgroup analyses and other…

Read More “Documentation of Multiplicity Strategy in Submission Packages” »